Harvard Bioscience (HBIO) Enterprise Value (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Enterprise Value data on file, last reported at -$7.1 million in Q1 2026.

• On a quarterly basis, Enterprise Value fell 27.98% year-over-year to -$7.1 million in Q1 2026; TTM through Mar 2026 was -$7.1 million, a 27.98% decrease from a year earlier, with the FY2025 full-year figure at -$8.6 million, down 109.69% from the prior year.
• Enterprise Value for Q1 2026 stood at -$7.1 million, up from -$8.6 million in the prior quarter.
• Over the last five years, Enterprise Value for HBIO reached as high as -$3.8 million in Q1 2023 and fell as low as -$8.6 million in Q4 2025.
• Historically, Enterprise Value has averaged -$5.3 million across 5 years, with a median of -$4.6 million in 2024.
• Across the five-year window, Enterprise Value soared 42.36% in 2022 and slumped 109.69% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$4.5 million in 2022, then advanced by 4.99% to -$4.3 million in 2023, then gained by 4.09% to -$4.1 million in 2024, then slumped by 109.69% to -$8.6 million in 2025, then grew by 17.6% to -$7.1 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$7.1 million in Q1 2026, -$8.6 million in Q4 2025, and -$6.8 million in Q3 2025.